Status:
COMPLETED
Phase 2 Study - Erdosteine in Patients With CB/COPD
Lead Sponsor:
Adams Respiratory Therapeutics
Conditions:
Chronic Bronchitis
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
This clinical study is designed to explore dose ranging and identify methods to demonstrate the efficacy of Erdosteine in patients with stable Chronic Bronchitis associated with Chronic Obstructive Pu...
Eligibility Criteria
Inclusion
- Adult patients with a clinical diagnosis of stable CB associated with COPD will be entered into this study. CB is diagnosed clinically in patients who have a documented smoking history and who have a daily productive cough for at least 3 months per year over at least 2 consecutive years in the absence of other causes of chronic cough. COPD is defined by the presence of airflow obstruction from spirometry
Exclusion
- asthma, bronchiectasis, or cystic fibrosis; active history of lung cancer, respiratory failure, or a need for long-term oxygen therapy;
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00338507
Start Date
March 1 2006
Last Update
December 6 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Omnicare Clinical Research
King of Prussia, Pennsylvania, United States, 19406